IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Kyowa Hakko Kirin subsidiary to acquire Archimedes Pharma

1:35 PM MDT | July 14, 2014 | Natasha Alperowicz

Kyowa Hakko Kirin’s (KHK; Tokyo) subsidiary ProStrakan Group (Galashiels, UK) has agreed with Novo to purchase the entire share capital of Archimedes Pharma (Reading, UK) for £230 million ($393.8 million) in cash. Archimedes is a fast-growing, Europe-based specialty pharmaceutical company providing novel and advanced treatments within the therapeutic areas of pain, oncology, and critical care. Its largest product is PecFent, a nasal spray used to manage breakthrough cancer pain in patients who are already receiving maintenance opioid therapy for...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa